Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Carcinoma of the prostate

5

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

5

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Estrogen receptor alpha

5

Estrogen receptor beta

5

Microtubule-associated protein 1A

5

Microtubule-associated protein 2

5

endothelial cell proliferation

5

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1981

5

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Palliative

5

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

5

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Bastian Werk, W. Germany

5

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

5

FDA UNII

5

PUBCHEM

5

SMS_ID

5

CHEBI

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other antineoplastic agents

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

4

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ESTRAMUSTINE

35LT29625A

Export Data
Search for Structure

Status:

US Approved Rx (1981)

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

endothelial cell proliferation

Estrogen receptor beta

Estrogen receptor alpha

Microtubule-associated protein 1A

Microtubule-associated protein 2

Conditions:

Carcinoma of the prostate

Estramustine is an antineoplastic agent indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Estramustine is a combination of estradiol with nitrogen mustard. In vivo, the nitrogen-mustard mo...

iety becomes active and participates in alkylation of DNA or other cellular components. This causes DNA damage in rapidly dividing cancerous cells leading to cell death and ideally, tumor shrinkage. Also, due to the drugs estrogen component, it can bind more selectively to active estrogen receptors. Used for the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate.

ESTRAMUSTINE PHOSPHATE MEGLUMINE

C89YOK4N2S

Export Data
Search for Structure

Status:

US Approved Rx (1981)

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

endothelial cell proliferation

Estrogen receptor beta

Estrogen receptor alpha

Microtubule-associated protein 1A

Microtubule-associated protein 2

Conditions:

Carcinoma of the prostate

Estramustine is an antineoplastic agent indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Estramustine is a combination of estradiol with nitrogen mustard. In vivo, the nitrogen-mustard mo...

iety becomes active and participates in alkylation of DNA or other cellular components. This causes DNA damage in rapidly dividing cancerous cells leading to cell death and ideally, tumor shrinkage. Also, due to the drugs estrogen component, it can bind more selectively to active estrogen receptors. Used for the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate.

ESTRAMUSTINE PHOSPHATE SODIUM

75F375MT2N

Export Data
Search for Structure

Status:

US Approved Rx (1981)

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

endothelial cell proliferation

Estrogen receptor beta

Estrogen receptor alpha

Microtubule-associated protein 1A

Microtubule-associated protein 2

Conditions:

Carcinoma of the prostate

Estramustine is an antineoplastic agent indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Estramustine is a combination of estradiol with nitrogen mustard. In vivo, the nitrogen-mustard mo...

iety becomes active and participates in alkylation of DNA or other cellular components. This causes DNA damage in rapidly dividing cancerous cells leading to cell death and ideally, tumor shrinkage. Also, due to the drugs estrogen component, it can bind more selectively to active estrogen receptors. Used for the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate.

ESTRAMUSTINE PHOSPHATE SODIUM ANHYDROUS

IQ856M1R16

Export Data
Search for Structure

Status:

US Approved Rx (1981)

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

endothelial cell proliferation

Estrogen receptor beta

Estrogen receptor alpha

Microtubule-associated protein 1A

Microtubule-associated protein 2

Conditions:

Carcinoma of the prostate

Estramustine is an antineoplastic agent indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Estramustine is a combination of estradiol with nitrogen mustard. In vivo, the nitrogen-mustard mo...

iety becomes active and participates in alkylation of DNA or other cellular components. This causes DNA damage in rapidly dividing cancerous cells leading to cell death and ideally, tumor shrinkage. Also, due to the drugs estrogen component, it can bind more selectively to active estrogen receptors. Used for the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate.

ESTRAMUSTINE PHOSPHATE

MUZ9585Y7B

Export Data
Search for Structure

Status:

US Approved Rx (1981)

First approved in 1981

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

endothelial cell proliferation

Estrogen receptor beta

Estrogen receptor alpha

Microtubule-associated protein 1A

Microtubule-associated protein 2

Conditions:

Carcinoma of the prostate

Estramustine is an antineoplastic agent indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Estramustine is a combination of estradiol with nitrogen mustard. In vivo, the nitrogen-mustard mo...

iety becomes active and participates in alkylation of DNA or other cellular components. This causes DNA damage in rapidly dividing cancerous cells leading to cell death and ideally, tumor shrinkage. Also, due to the drugs estrogen component, it can bind more selectively to active estrogen receptors. Used for the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1